|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:ATCCode
|
gptkb:N04BC09
|
|
gptkbp:bioavailability
|
37%
|
|
gptkbp:brand
|
gptkb:Neupro
|
|
gptkbp:CASNumber
|
gptkb:99755-59-6
|
|
gptkbp:drugClass
|
gptkb:dopamine_agonist
|
|
gptkbp:halfLife
|
5-7 hours
|
|
gptkbp:hasEliminationRoute
|
urine
feces
|
|
gptkbp:hasInChIKey
|
gptkb:QFFGVLORLPOAEC-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C17H19NO3
|
|
gptkbp:hasPatent
|
US4767811A
|
|
gptkbp:hasSMILES
|
CC1=CC2=C(C=C1)C3CCN(CC3)CC2OC(=O)C
|
|
gptkbp:hasTherapeuticUse
|
gptkb:Parkinson's_disease
gptkb:restless_legs_syndrome
|
|
gptkbp:hasUNII
|
KX2P88QY2P
|
|
gptkbp:isActiveAgainst
|
gptkb:dopamine_receptor_D2
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:UCB_Pharma
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
285.34
|
|
gptkbp:PubChem_CID
|
5281081
CHEBI:8880
DB05271
|
|
gptkbp:routeOfAdministration
|
transdermal
|
|
gptkbp:sideEffect
|
nausea
dizziness
somnolence
application site reactions
|
|
gptkbp:synonym
|
gptkb:Rotigotine
|
|
gptkbp:target
|
gptkb:dopamine_receptor_D1
gptkb:dopamine_receptor_D2
gptkb:dopamine_receptor_D3
|
|
gptkbp:bfsParent
|
gptkb:SR141716A
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL37541
|